Related Experiment Video
Updated: Feb 16, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Treatment of hepatitis C in special populations
Goki Suda1, Koji Ogawa2, Kenichi Morikawa2
1Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan. gsudgast@pop.med.hokudai.ac.jp.
Insights
Direct-acting antivirals (DAAs) offer a highly effective treatment for Hepatitis C virus (HCV) infection in special populations. These interferon-free therapies achieve high sustained viral response rates with fewer adverse events.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and cancer.
- HCV poses significant challenges in special populations like hemodialysis and liver transplant patients, often leading to poor outcomes.
- Co-infection with human immunodeficiency virus (HIV) accelerates liver fibrosis in HCV patients.
Purpose of the Study:
- To highlight the urgent need for effective Hepatitis C virus (HCV) treatment in vulnerable patient groups.
- To evaluate the efficacy and safety of novel direct-acting antivirals (DAAs) compared to interferon-based therapies for HCV.
- To assess the impact of DAAs on sustained viral response and adverse events in special populations.
Main Methods:
- Review of current literature on Hepatitis C virus (HCV) treatment strategies.
- Analysis of outcomes in hemodialysis, liver transplantation, and HIV co-infected patients treated with interferon-based therapies.
- Evaluation of clinical trial data for interferon-free direct-acting antiviral (DAA) regimens in special populations.
Main Results:
- Interferon-based therapies demonstrated limited efficacy and higher adverse events in special populations.
- Interferon-free direct-acting antiviral (DAA) regimens achieved sustained viral response rates exceeding 90% in these groups.
- DAA treatment was associated with a significantly lower incidence and severity of adverse events compared to older therapies.
Conclusions:
- Direct-acting antivirals (DAAs) represent a transformative advancement in treating Hepatitis C virus (HCV) infection.
- Interferon-free DAA therapy is highly effective and well-tolerated in hemodialysis, liver transplantation, and HIV co-infected patients.
- DAAs provide a crucial therapeutic option for improving outcomes in special populations affected by HCV.
Abstract:
Hepatitis C virus (HCV) infection is one of the primary causes of liver cirrhosis and hepatocellular carcinoma. In hemodialysis patients, the rate of HCV infection is high and is moreover associated with a poor prognosis. In liver transplantation patients with HCV infection, recurrent HCV infection is universal, and re-infected HCV causes rapid progression of liver fibrosis and graft loss. Additionally, in patients with HCV and human immunodeficiency virus (HIV) co-infection, liver fibrosis progresses rapidly. Thus, there is an acute need for prompt treatment of HCV infection in these special populations (i.e., hemodialysis, liver transplantation, HIV co-infection). However, until recently, the standard anti-HCV treatment involved the use of interferon-based therapy. In these special populations, interferon-based therapies could not achieve a high rate of sustained viral response and moreover were associated with a higher rate of adverse events. With the development of novel direct-acting antivirals (DAAs), the landscape of anti-HCV therapy for special populations has changed dramatically. Indeed, in special populations treated with interferon-free DAAs, the sustained viral response rate was above 90%, with a lower incidence and severity of adverse events.
Related Concept Videos
Special Staining Techniques
Conservation of Small Populations
What is Population Genetics?
Population Growth
Introduction to Special Senses
What are Populations and Communities?

